118 related articles for article (PubMed ID: 35396035)
1. Real world analysis of cardiac adverse events associated with clozapine: A pharmacovigilance analysis using food and drug administration adverse event reporting system.
Thotamgari SR; Bath AS; Dhaliwal L; Kommineni SK; Aujla P; Brar V
Gen Hosp Psychiatry; 2022; 78():123-125. PubMed ID: 35396035
[No Abstract] [Full Text] [Related]
2. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
3. Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions.
De Leon J; Sanz EJ; De Las Cuevas C
Schizophr Bull; 2020 Jan; 46(1):1-3. PubMed ID: 31901099
[No Abstract] [Full Text] [Related]
4. Risk of appendicitis associated with the use of clozapine: A pharmacovigilance study.
Uwai Y; Nabekura T
Asian J Psychiatr; 2022 Nov; 77():103264. PubMed ID: 36150349
[No Abstract] [Full Text] [Related]
5. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Sato K; Mano T; Iwata A; Toda T
Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
[TBL] [Abstract][Full Text] [Related]
6. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
7. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-induced acquired haemophilia: A pharmacovigilance analysis of the FDA adverse event reporting system.
Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
Haemophilia; 2022 Sep; 28(5):e145-e148. PubMed ID: 35895993
[No Abstract] [Full Text] [Related]
9. Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.
Vickers-Smith R; Sun J; Charnigo RJ; Lofwall MR; Walsh SL; Havens JR
Drug Alcohol Depend; 2020 Jan; 206():107709. PubMed ID: 31732295
[TBL] [Abstract][Full Text] [Related]
10. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Shu Y; Ding Y; Dai B; Zhang Q
Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
[TBL] [Abstract][Full Text] [Related]
11. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
[No Abstract] [Full Text] [Related]
12. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
13. Safety of clozapine use during pregnancy: Analysis of international pharmacovigilance data.
Beex-Oosterhuis MM; Samb A; Heerdink ER; Souverein PC; Van Gool AR; Meyboom RHB; van Marum RJ
Pharmacoepidemiol Drug Saf; 2020 Jun; 29(6):725-735. PubMed ID: 32378285
[TBL] [Abstract][Full Text] [Related]
14. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database.
Mazhar F; Battini V; Gringeri M; Pozzi M; Mosini G; Marran AMN; Akram S; van Manen RP; Radice S; Clementi E; Carnovale C
Expert Opin Biol Ther; 2021 Sep; 21(9):1281-1290. PubMed ID: 34191656
[TBL] [Abstract][Full Text] [Related]
15. Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.
Jimenez J; Gwillim EC; Kosche C; Figueiredo A; Rauck C; Rangel SM; Choi J; West DP; Nardone B; Lacouture ME
J Am Acad Dermatol; 2020 Sep; 83(3):955-957. PubMed ID: 32014533
[No Abstract] [Full Text] [Related]
16. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of Information on Drug Adverse Reactions Using U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)].
Nango D; Sekizuka T; Goto M; Echizen H
Yakugaku Zasshi; 2022; 142(4):341-344. PubMed ID: 35370189
[TBL] [Abstract][Full Text] [Related]
18. Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system.
Gatti M; Fusaroli M; Raschi E; Moretti U; Poluzzi E; De Ponti F
Expert Opin Drug Saf; 2021 Nov; 20(11):1421-1431. PubMed ID: 34280062
[TBL] [Abstract][Full Text] [Related]
19. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
20. Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system.
Aggarwal P
Expert Opin Drug Saf; 2019 Jul; 18(7):623-633. PubMed ID: 31088310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
